COPD affects roughly 480 million people worldwide, making it one of the most common chronic diseases on the planet. About 10.6% of adults aged 40 and older have some degree of the condition, and it ranks as the fourth leading cause of death globally, responsible for 3.5 million deaths in 2021 alone. Despite those numbers, the true scale is likely even larger: an estimated 70% of people with COPD have never been diagnosed.
Prevalence in the United States
In the U.S., 4.2% of adults have been diagnosed with COPD, emphysema, or chronic bronchitis, based on 2024 national survey data from the CDC. That figure reflects only people who know they have the condition. Because COPD develops gradually and early symptoms like mild breathlessness are easy to dismiss, the actual number of Americans living with it is considerably higher.
Prevalence varies significantly by region. States in the Southeast and Appalachia consistently report higher rates, driven by a combination of higher smoking rates, occupational exposures (mining, manufacturing), and lower access to healthcare. Rural areas tend to have more cases than urban ones for similar reasons.
How Age Changes the Picture
COPD is overwhelmingly a disease of middle and older age. Using lung function testing on a representative sample of Americans aged 40 to 80, researchers found that roughly 22% of adults between 40 and 64 met the criteria for COPD, compared to nearly 38% of those aged 65 to 80. Those numbers are far higher than diagnosis rates suggest, which again points to a massive gap between how many people have the disease and how many know it.
The steep jump after 65 makes sense biologically. Lung function naturally declines with age, and decades of cumulative exposure to cigarette smoke, air pollution, or workplace dust compound that decline. By the time symptoms become noticeable enough to prompt a doctor’s visit, the disease has often been progressing for years.
Men, Women, and the Narrowing Gap
Globally, COPD is more common in men than women. A large meta-analysis covering more than 150 studies found a prevalence of about 9.2% in men versus 6.2% in women. That gap has been narrowing for decades, largely because smoking rates among women rose sharply in the mid-20th century and the health consequences followed with a delay of several decades.
In North America, the difference between men and women is especially small: roughly 8.1% versus 7.3%. In Europe, the gap remains wider at about 9.1% in men and 6.1% in women. Women with COPD also tend to be diagnosed later, in part because clinicians have historically associated the disease more strongly with men. There is growing evidence that women may be more susceptible to lung damage from the same level of smoke exposure, though the reasons are still being studied.
COPD in People Who Never Smoked
Smoking is the leading risk factor, but COPD is not exclusively a smoker’s disease. Data from the international Burden of Obstructive Lung Disease study found that about 28% of all COPD cases occur in people who have never smoked. Among those with mild obstruction, never-smokers made up a third of cases. Even among those with moderate to severe disease, nearly one in four had never smoked.
The non-smoking causes include long-term exposure to indoor air pollution (particularly from cooking with biomass fuels in poorly ventilated homes), occupational dust and chemical fumes, outdoor air pollution, and a history of childhood respiratory infections or asthma. A rare genetic condition that reduces levels of a protective protein in the lungs can also cause COPD without any smoking history. These non-smoking causes are especially significant in low- and middle-income countries, where indoor air pollution from solid fuels remains widespread.
The Underdiagnosis Problem
Perhaps the most striking statistic about COPD is how many people have it without knowing. About 70% of cases worldwide go undiagnosed, particularly in low- and middle-income countries where access to lung function testing (spirometry) is limited. But underdiagnosis is common in wealthy countries too. Many people chalk up their breathlessness or chronic cough to aging, being out of shape, or allergies, and never mention it to a doctor.
This matters because earlier detection allows for interventions that slow progression. Quitting smoking at the first sign of airflow limitation preserves far more lung function than quitting after the disease has advanced. Pulmonary rehabilitation, inhaler therapy, and avoiding further exposures are all more effective when started earlier. By the time someone shows up in an emergency room struggling to breathe, significant and irreversible damage has already occurred.
Where the Numbers Are Heading
Global COPD cases are projected to rise from 480 million in 2020 to roughly 592 million by 2050, an increase of about 23%. That growth is driven primarily by aging populations. As more people worldwide live into their 70s and 80s, the pool of people old enough to develop COPD expands. The overall percentage of the eligible population with COPD may actually dip slightly, from 10.6% to 9.5%, as smoking rates continue to decline in many countries, but the raw number of cases will climb substantially.
The economic toll is enormous. One modeling study estimated that COPD will cost the global economy $4.3 trillion between 2020 and 2050, equivalent to a yearly drag of about 0.1% on global GDP. Those costs include direct medical spending, hospitalizations, and lost productivity from disability and early death.